Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of “Hold” from Brokerages

Posted by Geri Gentry on Aug 28th, 2026

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average rating of “Hold” from the twenty-three research firms that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $21.1522.

A number of research firms have recently weighed in on NTLA. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday. Wolfe Research lowered shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Wedbush lifted their price target on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the company a “neutral” rating in a report on Friday, July 10th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research report on Tuesday.

Read Our Latest Report on NTLA

Intellia Therapeutics Trading Down 0.6%

NTLA opened at $13.11 on Friday. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25. The company has a market capitalization of $1.84 billion, a PE ratio of -3.90 and a beta of 1.81. The firm’s 50 day simple moving average is $13.31 and its two-hundred day simple moving average is $13.38.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.80). The firm had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company’s revenue for the quarter was down 46.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.98) EPS. Equities analysts forecast that Intellia Therapeutics will post -3.21 earnings per share for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. This trade represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds have recently added to or reduced their stakes in NTLA. Oppenheimer & Co. Inc. boosted its holdings in Intellia Therapeutics by 0.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after acquiring an additional 808 shares during the period. Comerica Bank increased its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the period. PNC Financial Services Group Inc. increased its stake in Intellia Therapeutics by 36.4% in the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after purchasing an additional 948 shares during the period. Wealthfront Advisers LLC lifted its position in shares of Intellia Therapeutics by 7.6% during the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock worth $185,000 after purchasing an additional 1,018 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Intellia Therapeutics by 2.7% during the second quarter. Wellington Management Group LLP now owns 43,484 shares of the company’s stock worth $736,000 after purchasing an additional 1,125 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.